Search
Dihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedAlpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalAlectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesMaropitant
go.drugbank.com/drugs/DB11427ExperimentalVet approvedMaropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesGrazoprevir
go.drugbank.com/drugs/DB11575ApprovedGrazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that i...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnAsunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genoty...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesVelpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsArtenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsCurcumin
go.drugbank.com/drugs/DB11672ApprovedInvestigationalCurcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglyce...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalMyelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalTo date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administer...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors